LEO Pharma

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis

Share
Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies – which included 3,712 people with moderate-to-severe psoriasis – shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100. In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100.1 Study authors measured ‘sustained PASI 100’ as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period at or after week 16.1

Because the sub-populations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the study authors did not apply statistical comparisons.1

Newer treatments for moderate-to-severe psoriasis have made it possible for patients to completely clear their skin, but the disease fluctuates over time, so we wanted to explore how fast and for how long patients can count on having complete skin clearance,” saidProfessor Lluís Puig, Director, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona. “These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab. That difference can have a big impact on patients’ quality of life.”

PASI scores are used in clinical trials for psoriasis treatments to measure a change in disease severity. Most psoriasis trials have used PASI 75 (75% clearing of skin lesions) as a primary endpoint,[i] however PASI 100 (100% clearing of skin lesions) has become commonly used in more recent studies.[ii] In its phase 3 clinical trial program, which was the largest for a biologic treatment for psoriasis at the time it was conducted, brodalumab was the first biologic that investigators evaluated using PASI 90/100 scores as a primary endpoint for patients with moderate-to-severe plaque psoriasis.

A 2018 report of 7,644 people living with psoriasis in twelve European countries found that an average of 49% would be happier if their skin was completely free of lesions and symptoms like itchiness and scaling. [iii] Nearly one in four (24%) felt achieving skin clearance would allow them to live their best possible life and gave their potential happiness level a top ranking on a 10-point happiness scale. However, nearly two-thirds (63%) of respondents believed achieving clear skin is impossible or very unlikely.4

- Ends - 

NOTES TO EDITORS

 

About brodalumab

Brodalumab(marketed as Kyntheum® in the European Union) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.[i] It is the first and only biologic treatment for psoriasis that selectively targets the interleukin-17 (IL-17) receptor subunit A.[ii],[iii] The IL-17 cytokines – a family of proteins involved in immune responses– send signals through the IL-17 receptors, which cause the inflammation associated with psoriasis. Other anti-IL-17 biologics target the IL-17A cytokine alone and not the IL-17 receptor.6,[iv],[v],[vi]

LEO Pharma has a partnership agreement with AstraZeneca, granting LEO Pharma exclusive licence to develop and commercialise brodalumab in Europe. Outside of Europe, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals) has the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are held by Kyowa Hakko Kirin Co. Ltd. Brodalumab was granted marketing authorisation by the European Commission in July 2017.8

About psoriasis

An estimated 125 million people worldwide live with psoriasis,[vii] including nearly 14 million Europeans.[viii] It is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.[ix] The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).13

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.13 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,[x]including heart disease[xi],[xii],[xiii] and metabolic diseases (a combination of diabetes, high blood pressure and obesity).[xiv] Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.[xv] According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.13

References

[1]     Puig L, et al. Sustained responses of treatment by brodalumab compared to ustekinumab, E-poster: SPIN2019-ABS-195.

[2]     Feldman, R, Ann Rheum Dis 2005;64 (Suppl II):ii65–ii68.

[3]     Zheng J, Br J Dermatol 2017;176(3):576.

[4]     PsoClear Report 2018. https://psohappy.org/psoclear2018

[5]     European Commission, Community register of medicinal products for human use, Kyntheum® (brodalumab). Available at: http://ec.europa.eu/health/documents/community-register/html/h1155.htm(Accessed March 2019).

[6]     Campa M, et al. Dermatol Ther 2016;6:1–12.

[7]     Coimbra S, et al. Core Evidence 2014;9:89–97.

[8]     Kyntheum®. Summary of Product Characteristics November 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003959/WC500232913.pdf (Accessed March 2019).

[9]     Cosentyx®. Summary of Product Characteristics. October 2018. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (Accessed March 2019).

[10]     Taltz®. Summary of Product Characteristics. August 2018. Available at: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf (Accessed March 2019).

[11]     The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed March 2019).

[12]     Ortonne J, et al. Eur J Dermatol 2004;14:41–45.

[13]       World Health Organization (WHO). Global Report on Psoriasis. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed March 2019).

[14]     Reich K. Eur Acad Dermatol Venereol 2012;26(2):3–11.

[15]     Gelfand JM, et al. JAMA 2006;296:1735–41.

[16]     Ahlehoff O, et al. Eur Heart J 2012;33:2054–64.

[17]     Lowes MA, et al. Ann Rev Immunol 2014;32:227–35.

[18]     Langan SM, et al. J Invest Dermatol 2012;132(3 Pt 1):556–562.

[19]     Dalgard F, et al. JID 2015;135(4):984 –991.

Contacts

LEO Pharma A/S: Trine Juul Wengel, Global External Communications
tewdk@leo-pharma.com, Tel.: +45 72 60 86 18

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.

For more information about LEO Pharma, visit www.leo-pharma.com.

Facebook: www.facebook.com/LEOPharmaAS

LinkedIn: www.linkedin.com/company/leo-pharma

Twitter: www.twitter.com/leohealthyskin

YouTube: www.youtube.com/leopharmaglobal

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse

LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.

LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse

Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases

LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis19.9.2025 16:00:00 CEST | Pressemeddelelse

Late-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)18.9.2025 15:45:00 CEST | Pressemeddelelse

The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17

LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse

Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye